The quality of warfarin prescribing and monitoring in Veterans Affairs nursing homes
- PMID: 20662956
- PMCID: PMC2955176
- DOI: 10.1111/j.1532-5415.2010.02967.x
The quality of warfarin prescribing and monitoring in Veterans Affairs nursing homes
Abstract
Objectives: To describe the quality of warfarin prescribing and monitoring in Veterans Affairs (VA) nursing homes and to assess the factors associated with maintaining a therapeutic international normalized ratio (INR).
Design: Retrospective cohort.
Setting: Five VA nursing homes.
Participants: All veterans who received warfarin between January 1 and June 30, 2008, at the nursing homes.
Measurements: Using medical records, the percentage of person-time spent in the target INR range, the proportion of patients with INRs in the therapeutic range on 50% or more of their person-days, and the frequency of INR monitoring were estimated. Multivariable logistic regression was used to identify factors associated with maintaining a therapeutic INR 50% or more of the time.
Results: Over 6 months, 160 patients received 10,380 person-days of warfarin. INRs were in the therapeutic range for 55% of the person-days, and 99% of the INR tests were repeated within 4 weeks of the previous result. On an individual level, 49% of patients had INRs in the target range for 50% or more of their person-days. Achieving this outcome was more likely in patients with prevalent warfarin use than with new use (adjusted odds ratio (AOR)=2.86, 95% confidence interval (CI)=1.06-7.72). Conversely, patients with a history of a stroke (AOR=0.38, 95% CI =0.18-0.80) were less likely to have therapeutic INRs for 50% or more of their days.
Conclusion: Warfarin appears to be prescribed and monitored effectively in VA nursing home patients. Future studies should focus on increasing time in therapeutic range in patients with poor INR control.
© 2010, Copyright the Authors. Journal compilation © 2010, The American Geriatrics Society.
Conflict of interest statement
Comment in
-
Warfarin prescribing in nursing homes.J Am Geriatr Soc. 2011 Jan;59(1):183-4. doi: 10.1111/j.1532-5415.2010.03224.x. J Am Geriatr Soc. 2011. PMID: 21226702 No abstract available.
Similar articles
-
Randomized trial of a warfarin communication protocol for nursing homes: an SBAR-based approach.Am J Med. 2011 Feb;124(2):179.e1-7. doi: 10.1016/j.amjmed.2010.09.017. Am J Med. 2011. PMID: 21295198 Free PMC article. Clinical Trial.
-
Quality of anticoagulation and use of warfarin-interacting medications in long-term care: a chart review.BMC Geriatr. 2008 Jul 3;8:13. doi: 10.1186/1471-2318-8-13. BMC Geriatr. 2008. PMID: 18598364 Free PMC article.
-
Outcomes associated with warfarin time in therapeutic range among US veterans with nonvalvular atrial fibrillation.Curr Med Res Opin. 2018 Mar;34(3):415-421. doi: 10.1080/03007995.2017.1384370. Epub 2017 Oct 3. Curr Med Res Opin. 2018. PMID: 28945114
-
Prospective study of the outcomes of ambulatory patients with excessive warfarin anticoagulation.Arch Intern Med. 2000 Jun 12;160(11):1612-7. doi: 10.1001/archinte.160.11.1612. Arch Intern Med. 2000. PMID: 10847254
-
Association Between Warfarin Control Metrics and Atrial Fibrillation Outcomes in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation.JAMA Cardiol. 2019 Aug 1;4(8):756-764. doi: 10.1001/jamacardio.2019.1960. JAMA Cardiol. 2019. PMID: 31268487 Free PMC article.
Cited by
-
Rosendaal linear interpolation method appraising of time in therapeutic range in patients with 12-week follow-up interval after mechanical heart valve replacement.Front Cardiovasc Med. 2022 Sep 9;9:925571. doi: 10.3389/fcvm.2022.925571. eCollection 2022. Front Cardiovasc Med. 2022. PMID: 36158842 Free PMC article.
-
Magnitudes of Risk Factors of Venous Thromboembolism and Quality of Anticoagulant Therapy in Ethiopia: A Systematic Review.Vasc Health Risk Manag. 2022 Apr 11;18:245-252. doi: 10.2147/VHRM.S347667. eCollection 2022. Vasc Health Risk Manag. 2022. PMID: 35431550 Free PMC article. Review.
-
Impact of an extended International Normalized Ratio follow-up interval on healthcare use among veteran patients on stable warfarin doses.Am J Health Syst Pharm. 2019 Oct 30;76(22):1848-1852. doi: 10.1093/ajhp/zxz209. Am J Health Syst Pharm. 2019. PMID: 31589272 Free PMC article.
-
Quality of anticoagulation management with warfarin among outpatients in a tertiary hospital in Addis Ababa, Ethiopia: a retrospective cross-sectional study.BMC Health Serv Res. 2017 Jun 6;17(1):389. doi: 10.1186/s12913-017-2330-0. BMC Health Serv Res. 2017. PMID: 28587606 Free PMC article.
-
Use of vitamin K antagonist therapy in geriatrics: a French national survey from the French Society of Geriatrics and Gerontology (SFGG).Drugs Aging. 2013 Dec;30(12):1019-28. doi: 10.1007/s40266-013-0127-3. Drugs Aging. 2013. PMID: 24170234
References
-
- Gurwitz JH, Field TS, Radford MJ, et al. The safety of warfarin therapy in the nursing home setting. Am J Med. 2007;120:539–544. - PubMed
-
- Gurwitz JH, Field TS, Avorn J, et al. Incidence and preventability of adverse drug events in nursing homes. Am J Med. 2000;109:87–94. - PubMed
-
- McCormick D, Gurwitz JH, Goldberg RJ, et al. Prevalence and quality of warfarin use for patients with atrial fibrillation in the long-term care setting. Arch Intern Med. 2001;161:2458–2463. - PubMed
-
- Go AS, Fang MC, Chang Y, et al. Abstract 3590: Defining a threshold of anticoagulation quality that leads to net clinical benefit in atrial fibrillation: The ATRIA study. Circulation. 2007;116(16 supplement):II–813.
Publication types
MeSH terms
Substances
Grants and funding
- R01 AG034056/AG/NIA NIH HHS/United States
- K07 AG033174-02/AG/NIA NIH HHS/United States
- R01 NR010135/NR/NINR NIH HHS/United States
- K07 AG033174-01A1/AG/NIA NIH HHS/United States
- P30AG024827/AG/NIA NIH HHS/United States
- R34 MH082682/MH/NIMH NIH HHS/United States
- R01 HS017695/HS/AHRQ HHS/United States
- K12 RR023267/RR/NCRR NIH HHS/United States
- R01AG034056/AG/NIA NIH HHS/United States
- T32 AG021885/AG/NIA NIH HHS/United States
- K07 AG033174-03/AG/NIA NIH HHS/United States
- K07AG033174/AG/NIA NIH HHS/United States
- R01AG027017/AG/NIA NIH HHS/United States
- K07 AG033174/AG/NIA NIH HHS/United States
- P30 AG024827/AG/NIA NIH HHS/United States
- UL1 TR000005/TR/NCATS NIH HHS/United States
- R01 AG027017/AG/NIA NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical
